CD4+FoxP3+ regulatory T-cells in human systemic lupus erythematosus  by Suen, Jau-Ling & Chiang, Bor-Luen
Journal of the Formosan Medical Association (2012) 111, 465e470Available online at www.sciencedirect.com
journal homepage: www.jfma-onl ine.comREVIEW ARTICLE
CD4DFoxP3D regulatory T-cells in human systemic
lupus erythematosusJau-Ling Suen a,b, Bor-Luen Chiang c,*aGraduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC
bDepartment of Microbiology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan,
ROC
cDepartment of Pediatrics, College of Medicine, National Taiwan University, Taipei, Taiwan, ROC
Received 15 November 2011; received in revised form 9 May 2012; accepted 21 May 2012KEYWORDS
FoxP3;
regulatory T-cell;
systemic lupus
erythematosus* Corresponding author. Departme
Taiwan University Hospital, 1 Chang-
ROC.
E-mail address: gicmbor@ntu.edu.
0929-6646/$ - see front matter Copyr
http://dx.doi.org/10.1016/j.jfma.201Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by a loss
of immune tolerance to self antigens and by the persistent production of pathogenic autoan-
tibodies. Recent studies have suggested a dysregulation of regulatory T-cells (Tregs), particu-
larly CD4þCD25highFoxP3þ (forkhead box P3) Tregs, as one of the major factors conferring the
risk for expression of human autoimmune diseases, including SLE. However, detailed studies of
CD4þFoxP3þ T-cells in patients with SLE remain limited. We attempt here to integrate the
current experimental evidence to delineate the role of CD4þCD25high and other subsets of
CD4þFoxP3þ T-cells in human SLE.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Immune tolerance to autoantigens is a tightly regulated
process. Deletion of self-reactive T-cells in the thymus is an
important mechanism for self-tolerance. However, some
autoreactive cells still can escape negative selection into
the periphery.
Peripheral tolerance is maintained a number of ways,
including CD4þCD25þ regulatory T-cells (Tregs) that activelynt of Pediatrics, National
Teh Street, Taipei, Taiwan,
tw (B.-L. Chiang).
ight ª 2012, Elsevier Taiwan LLC
2.05.013suppress autoimmunity and control immune homeostasis.
Tregs represent 5e10% of CD4þ T-cells in both humans and
mice.1,2 They are characterized by the constitutive expres-
sion of CD25 [interleukin-2 (IL-2) receptor alpha chain],
cytotoxic T-lymphocyte antigen 4 (CTLA-4), glucocorticoid-
induced tumor necrosis factor receptor-related protein
(GITR), and transcriptional repressor forkhead box P3
(FoxP3), and a low level or nonexpression of CD127 (IL-7
receptor).3 CD25 used to be seen as the only reliable marker
for Tregs; however, activated CD4þ T-cells also express
CD25. In contrast, FoxP3 has been shown to be specifically
expressed by Tregs and able to program the development and
function of Tregs.4,5 Further, CD127 expression inversely
correlates with FoxP3 irrespective of CD25 expression in both& Formosan Medical Association. All rights reserved.
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CD4 expression can be used to isolate viable FoxP3þ T-cells
(CD3þCD4þCD127e) for functional studies of Tregs.
In addition, to further characterize human CD4þFoxP3þ
T-cells, they can be separated into three subsets by the
expression of CD45RA, FoxP3, and CD25.7 These subsets
are (1) CD45RAþFoxP3low(CD25low) resting Tregs, (2)
CD45RAeFoxP3high(CD25high) activated Tregs, and (3)
CD45RAeFoxP3low(CD25low) non-Tregs. Resting Tregs, which
come from the thymus, can be differentiated into activated
Tregs in vitro and in vivo. Both resting Tregs and activated
Tregs have suppressive activity in vitro. In contrast,
CD45RAeFoxP3low T-cells can secrete IL-2 and interferon-
gamma (IFN-g) and exhibit little suppressive activity.
Thus, the identification of FoxP3 and CD45RA expression as
a marker for Tregs is important in order to further analyze
their role in disease states. Thus, FoxP3 combined with
CD127 and CD45RA is currently the best marker for the
identification of different subsets of human FoxP3þ Tregs.The role of FoxP3 in Tregs
Based on the studies of scurfy mutant mice, which have
autoimmune lymphoproliferative disease, the Foxp3 gene
has been identified, and it has been shown that FoxP3 is
responsible for the scurfy phenotype.8 Several lines of
evidence demonstrate that FoxP3 is necessary and suffi-
cient for the development and function of Tregs in mice.
First, using FoxP3 reporter mice that were knockin with an
allele of the Foxp3-green fluorescent protein gene,9 it was
shown that the predominant type of FoxP3þ cells were
abTCRþCD4þ T-cells irrespective of CD25 expression. In
addition, both CD25þFoxP3þ and CD25eFoxP3þ T-cells can
act as suppressors in vitro.4 Second, ectopic expression of
FoxP3 in conventional CD4þCD25e T-cells converted those
cells to a regulatory phenotype. These converted FoxP3þ
T-cells can function as Tregs both in vitro and in vivo.4
Third, when mice lack functional FoxP3 proteins, via
either the scurfy mutation or a targeted mutation, they do
not display Treg activity and develop severe systemic
autoimmune diseases.5,9,10 In humans, the FOXP3 mutation
also leads to immune dysregulation, polyendocrinopathy,
enteropathy, X-linked (IPEX) disease with autoimmune
manifestations and defective Treg function.11,12
It has been demonstrated in both mice and humans that
FoxP3-expressing CD4þCD25þ T-cells can act as suppres-
sors. However, further characterization of FoxP3 expression
shows two major differences between humans and mice.
First, human CD4þCD25þ T-cells, but not murine cells, can
express two isoforms of FoxP3.13 One isoform represents
the homolog to murine FoxP3, whereas the other isoform is
encoded from an mRNA lacking exon 2.14 The sequences
encoded by exon 2 fall within the repressor domain of the
FoxP3 protein.14 To date, the role of the 6exon 2 isoform
in the function and development of Tregs, and whether or
not the same T-cells express both isoforms simultaneously,
remains unclear. Second, the regulation of FoxP3 expres-
sion is different between humans and mice. Activation-
induced expression of FoxP3 has been reported for
in vitro-stimulated human CD4þ T-cells14,15 but not mouse
cells.4 A recent study has demonstrated that humanCD4þFoxP3þ T-cells contain cytokine-secreting, non-
suppressive effector T-cells that are CD45RAeFoxP3low.7
These nonsuppressive CD45RAeFoxP3lowCD4þ T-cells may
correspond to in vitro activation-induced FoxP3-expressing
cells.14,15 In addition, not only the CD45RAeCD25high
subset,2 but also the CD45RAþCD25low subset in human
FoxP3þCD4þ T-cells displays suppressive activity in vitro
and in vivo.7 Thus, human FoxP3þ T-cells are heteroge-
neous in function and consist of not only suppressive Tregs,
but also nonsuppressive T-cells.Natural Tregs and adaptive Tregs
There are at least two populations of CD4þ Tregs in humans
and mice, defined by their origin. The first population of
CD4þ Tregs is natural Tregs, which are generated during
normal T-cell maturation in the thymus. These typically
express CD25, as well as CTLA-4 and GITR.16 This subset is
self-reactive and is involved in protection from autoim-
mune responses. Recently, two subsets of FoxP3þ natural
Tregs according to differential inducible costimulator
(ICOS) expression have been found in the human thymus
and periphery.17 ICOSþFoxP3þ Tregs secrete IL-10 to
suppress dendritic cell (DC) function, and transforming
growth factor beta (TGF-b) to suppress T-cell function,
whereas ICOSeFoxP3þ Tregs mainly secrete TGF-b to
mediate the suppressive function.
The second population is adaptive Tregs, which originate
from the thymus but are developed throughout the course
of the immune response in vivo. This population includes
TGF-b-expressing type 3 T-helper cells, IL-10-producing
type 1 regulatory T-cells, and peripherally converted
FoxP3þ Tregs.18 Research has shown that naı¨ve CD4þ T-cells
can be converted, de novo, into CD25þFoxP3þ and
CD25eFoxP3þ suppressor T-cells on subimmunogenic stim-
ulation.19 This de novo Treg conversion may be mediated
either by DCs with tolerogenic properties20 or by intestinal
DCs from lamina propria.21CD4DFoxP3D T-cells in systemic lupus
erythematosus
Systemic lupus erythematosus (SLE) is characterized by
dysregulated immunity with hyperactive T-cells and B-
cells. Lupus-prone mice with CD4þCD25þ Treg depletion
from thymectomy have an enhanced expansion of autor-
eactive T-cells and accelerated autoantibody produc-
tion.22 In contrast, treatment with CD4þCD25þ Tregs from
syngeneic normal mice can effectively abrogate the prog-
ress of autoimmune disease,23 as well as supplement with
in vitro-expanded Tregs24 and TGF-b-generated Tregs.25
Thus, the dysregulated immunity in lupus may be corre-
lated with the altered homeostasis or defective function of
Tregs.
A few studies have been performed to quantify the
frequency of CD4þCD25þ/high T-cells in patients with SLE.
These studies have shown that the frequency of
CD4þCD25þ/high T-cells is decreased in patients with
SLE.26,27 However, no correlation has been established
between the level of CD4þCD25þ/high T-cells and disease
Regulatory T-cells in systemic lupus erythematosus 467activity. Lee et al have shown an inverse correlation
between percentages of CD4þCD25þ T-cells and disease
activity, including SLE Disease Activity Index (SLEDAI) score
and serum anti-double-stranded DNA levels in pediatric
patients.28 Interestingly, this finding showed higher FoxP3
mRNA levels in CD4þ T-cells in active SLE compared with
normal controls and those with inactive SLE.
A recent study by Miyara et al29 also observed that
CD4þCD25high T-cell depletion in lupus patients was asso-
ciated with the clinical severity of the flare. These Tregs
with normal suppressive function did not redistribute to
lymph nodes or tissues and were sensitive to Fas-induced
apoptosis.29 This study suggests that the inappropriate
induction of Treg apoptosis is, at least in part, associated
with the depletion of CD4þCD25high T-cells in lupus
patients and thus relevant to SLE pathogenesis. However,
Valencia et al showed that CD4þCD25high T-cells from
patients with active SLE expressed reduced levels of FoxP3
and displayed a poor inhibitory activity on the proliferative
response of responding T-cells.30 Alvarado-Sanchez et al
showed that about one-third of lupus patients exhibited
a diminished suppressive function of CD4þCD25high T-cells,
but had a normal frequency of Tregs in their peripheral
blood.31
These conflicting results may be due to an imprecise
phenotypic definition of Tregs. Due to the unique expres-
sion pattern of human CD25 on activated CD4þ T-cells and
Tregs, it is difficult to draw the line between CD25high and
CD25low cells on fluorescence-activated cell sorting plots
(Fig. 1). However, by analyzing CD25 and FoxP3 expression
on CD4þ T-cells in conjunction, it becomes easier to
distinguish different subsets of T-cells.32 Therefore, if only
CD25 serves as a Treg marker, sorted CD25high Tregs could
display poor suppressive ability in vitro if they were
contaminated by CD25low effector T-cells. In contrast, strict
gating for high CD25 expression on CD4þ T-cells may result
in falsely low Treg numbers/frequency in human peripheral
blood mononuclear cells.
Five studies have examined FoxP3-expressing CD4þ T-
cells in patients with SLE (Table 1). All the studies showed
that SLE patients had higher CD4þCD25eFoxP3þ and/or
CD4þCD25þFoxP3þ T-cell frequencies than normal con-
trols.7,32e35 According to these studies, and based on the
findings of heterogeneous subsets in the function of human
FoxP3þ cells,7 SLE patients may have a defect in the
homeostatic control of different subsets of FoxP3þ cells.
These human FoxP3þ subsets are described separately as
follows.Figure 1 Characterization of different subsets of FoxP3þ T-
cells in a patient with systemic lupus erythematosus (SLE) and
a healthy individual. Peripheral blood mononuclear cells were
stained with fluorochrome-labeled anti-CD3, anti-CD4, anti-
CD25, and anti-FoxP3 monoclonal antibodies and analyzed using
a flow cytometer (LSRII, BD Biosciences). Dot plots show the
expression of FoxP3 (x-axis) and CD25 (y-axis) on gated
CD3þCD4þ T-cells from one healthy individual (upper panel) and
one patient with SLE (lower panel). Quadrants were established
using appropriate isotype controls. R1 Z CD25highFoxP3þ;
R2Z CD25lowFoxP3þ; R3Z CD25eFoxP3þ; R4Z CD25þFoxP3e.CD4DCD25highFoxP3D Tregs
Patients with active SLE have a significantly decreased
percentage and number of CD4þCD25highFoxP3þ Tregs
(corresponding to activated Tregs7; the R1 region in Fig. 1)
with normal suppressive activity in their peripheral blood.
This decrease is also correlated with disease activity.29,32,34
The global depletion of CD4þCD25highFoxP3þ Tregs may be
associated with their hypersensitivity to Fas-induced
apoptosis (Fig. 2).29 However, the mechanisms responsible
for the exacerbated susceptibility to apoptosis of human
lupus CD4þCD25highFoxP3þ Tregs still need to be clarified.CD4DCD25lowFoxP3D T-cells
As shown in Table 1,32e35 several studies have shown that
patients with active lupus also have an increased
percentage of CD4þCD25low/þFoxP3þ T-cells (the R2 region
in Fig. 1) in their peripheral blood. This population may
contain at least two subsets e CD45RAþ resting Tregs and
CD45RAe cytokine-secreting non-Tregs (Fig. 2).7 There are
two possible mechanisms to explain their high percentage
in patients with active lupus. The first one is that CD45RAþ
resting lupus Tregs (CD45RAþCD25lowFoxP3þ) may accumu-
late due to the global depletion of activated Tregs
(CD25highFoxP3þ), because activated Tregs can suppress the
proliferation of resting Tregs by negative feedback (Fig. 2).7
The second mechanism is that lupus CD45RAe cytokine-
secreting non-Tregs (CD45RAeCD25lowFoxP3þ) may consist
of a large portion of autoreactive CD4þ T-cells specific for
nuclear antigens, such as nucleosomes36 as these autor-
eactive T-cells continue expansion in vivo, especially in
patients with active SLE. Glucocorticoid treatment in
patients with inactive disease may be able to control this
expansion, so that the frequency of CD4þCD25lowFoxP3þ
T-cells in patients with inactive disease is lower than that
with active SLE.32 However, the functional delineation and
Table 1 Analysis of CD4þFoxP3þ T-cell subpopulations in human systemic lupus erythematosus.
Reference Percentage of CD4þ T-cells Ratio of FoxP3þ/FoxP3e Disease correlation Treg function
Lin et al33 FoxP3þ [
CD25þFoxP3þ [
NA SLEDAI NA
CD25eFoxP3þ [
Zhang et al35 CD25þFoxP3þ/
CD25eFoxP3þ [
NA Anti-dsDNA IgG CD4þCD25þ e normal
suppressive activity
Yan et al34 CD25þFoxP3þ(CD127low) [
CD25eFoxP3þ e NA
NA SLEDAI CD4þCD25high e normal
suppressive activity
Miyara et al7 CD45RAeFoxP3high(CD25high)Y
CD45RAþFoxP3low(CD25þ)[
CD45RAeFoxP3low(CD25þ)[
NA NA NA
Suen et al32 CD25highFoxP3þ(CD127low) Y
CD25lowFoxP3þ(CD127low) [
CD25highFoxP3þ/Teff Y
CD25lowFoxP3þ/Teff Y
Anti-dsDNA IgG
C3/C4 level
CD4þCD25high e normal
suppressive activity
CD25eFoxP3þ(CD127low) [ CD25eFoxP3þ/Teff/
CD25þFoxP3e(CD127þ) (Teff)[
dsDNA Z double-stranded DNA; NA Z not analyzed; Ig Z immunoglobulin; SLEDAI Z Systemic Lupus Erythematosus Disease Activity
Index; Teff Z effector T-cell (represented by CD4þCD25þFoxP3e T-cells); Treg Z regulatory T-cell.
468 J.-L. Suen, B.-L. Chiangdifferentiation dynamics of CD4þCD25lowFoxP3þ T-cells in
lupus still need to be explored.CD4DCD25eFoxP3D T-cells
Another important subset of FoxP3þ T-cells that has been
found to show a significant increase in frequency in SLE
patients is CD4þFoxP3þ T-cells without CD25 expression (the
R3 region in Fig. 1).32 The CD4þCD25e T-cells, irrespective of
their CD45RA expression, express little FoxP3 in normalFigure 2 Altered homeostasis of CD4þFoxP3þ T-cell subsets in pa
active lupus have a significantly decreased frequency of activated
CD25lowFoxP3low, CD25eFoxP3low, and CD25lowFoxP3e T-cell subsets.
hypersensitivity to Fas-induced apoptosis. Activated Tregs can sup
CD25lowFoxP3þ T-cells may contain resting Tregs and FoxP3þ non-Treg
been clarified. Another unique subset, CD25eFoxP3low T-cells, also has
largely unknown. This unique subset may represent adaptive Tregs th
Tregs. In addition, a significantly increased number of activated T-ce
patients. This subset may contain a large number of autoreactive T-c
(DCs) in the interferon-alpha-rich environment. AgZ antigen; APCZindividuals.7 Thus, this subset seems relatively unique to
SLE. However, the origin and function of this subset are at
present largely unknown.
There are several issues worth discussing here. The first
one is the function and origin of this unique subset in lupus.
Their FoxP3 protein may be transiently induced by activa-
tion, and this subset may display non-Treg activity. Second,
systemic inflammation can induce the differentiation of
naı¨ve CD4þ T-cells into CD25þFoxP3þ and CD25eFoxP3þ
Tregs, or so-called adaptive Tregs.18,19,32,37 This subset may
represent the adaptive Tregs in patients with SLE. Finally,tients with active systemic lupus erythematosus. Patients with
regulatory T-cells (Tregs; CD25highCD45RAeFoxP3high), increased
The depletion of activated Tregs may be associated with their
press the proliferation of resting Tregs via negative feedback.
s; however, the CD45RA expression level of this subset has not yet
been observed in patients; however, their origin and function are
at are differentiated from naı¨ve T-cells or FoxP3-expressing non-
lls (CD25lowCD45RAeFoxP3e) also exist in the peripheral blood of
ells that are activated by nucleosome-presenting dendritic cells
antigen-presenting cell; DCZ dendritic cell; IFNZ interferon.
Regulatory T-cells in systemic lupus erythematosus 469the increased frequency of CD25eFoxP3þ T-cells in patients
may compensate for the loss of CD25highFoxP3þ Tregs in
active SLE. However, this compensation may not be enough
to regulate the autoimmune response, as SLE patients have
altered relative ratios of CD25highFoxP3þ Tregs and
CD25lowFoxP3þ T-cells versus effector T-cells (Fig. 2).32
In contrast to those with SLE, Rheumatoid arthritis (RA)
patients have similar frequencies of CD4þFoxP3þ T-cells
irrespective of their CD25 expression compared with normal
controls.32,33 In addition, Franz et al showed that patients
with cutaneous lupus erythematosus had normal levels of
CD4þFoxP3þ T-cells in their peripheral blood, but
decreased levels in local skin lesions.38 This suggests that
the global dysregulation of decreased CD25highFoxP3þ Tregs
and increased CD25low/eFoxP3þ CD4þ T-cells seems to be
relatively unique to SLE. The mechanism clearly needs to
be investigated further.
Several pieces of evidence suggest that lupus DCs may
be responsible for this dysregulation.39,40 It has been shown
that IFN-a-producing antigen-presenting cells, such as
plasmacytoid DCs, play a vital role in the pathogenesis of
SLE.40 These IFN-a-producing antigen-presenting cells may
block Treg cell-mediated suppression in SLE patients.34 In
addition, the overproduction of IL-6 by DCs in lupus-prone
mice may mediate the impaired Treg function.41
Another major issue is the antigen specificity of Tregs in
SLE patients. Hahn et al demonstrated that functional
human Tregs can be induced by exposure to anti-DNA
immunoglobulin-based peptides.42 In addition, the FoxP3
expression level in lupus CD4þCD25high T-cells also clearly
increased when peripheral blood mononuclear cells from
patients stimulated with these self-peptides in vitro. Two
possibilities may explain the increase in number or FoxP3
level of CD4þCD25high T-cells with in vitro culture. First,
self peptides may directly promote the expansion of lupus
CD4þCD25high T-cells in vitro. Second, CD4þCD25high T-cells
may be derived from FoxP3-expressing CD25low or CD25e
T-cells after in vitro stimulation, which leads to the change
in phenotype from CD25low/e to CD25high without losing
FoxP3 expression. Thus, these studies suggest that dysre-
gulated Treg homeostasis may play an important role in the
pathogenesis of SLE.Potential implications of Treg immunotherapy
in SLE patients
In humans, small-scale trials have demonstrated that in vitro-
expanded Tregs under good-manufacturing practice condi-
tions can provide a beneficial effect in the management of
bone marrow transplantation.43e45 This suggests that Treg
therapy is another therapeutic strategy to control systemic
autoimmunity. Two approaches can be considered regarding
Treg therapy in patients with SLE. First, we could isolate
patients’ resting Tregs (CD25lowCD45RAþCD127eFoxP3þ) and
expand them in vitro to perform Treg therapy. Second, it has
been found that administration of a histone deacetylase
inhibitor in vivo significantly increases FoxP3 gene expression
and the suppressive function of Tregs through epigenetic
modification of FoxP3.46 Thus, it is worth examining whether
histone deacetylase inhibitor treatment can increase the
FoxP3 expression level in FoxP3-expressing lupus subsets(as shown in Fig. 2) and whether the increased FoxP3
expression enables those cells to display the suppressive
activity in vivo. If so, the autoimmune responses in patients
may be downregulated by these high percentages of lupus
FoxP3-expressing subsets.32
Summary
SLE patients have altered homeostasis in their CD4þFoxP3þ
T-cell subsets, that is, a decreased frequency of
CD4þCD25highFoxP3þ Tregs and an increased number of
CD4þFoxP3þ T-cells with CD25low or CD25e expression. One
should remember that FoxP3 is also transiently expression in
human nonregulatory T-cells.12,13 In contrast, murine FoxP3
expression is sufficient for the suppressive function of
Tregs.4 Thus, functional characterization is required for
each subset of lupus FoxP3þ T-cells in humans. Furthermore,
analyzing the function and origin of each subset will help us
to better understand the immune responses in cases of lupus
and to design antigen-specific immunotherapy for SLE.
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